Tandem Diabetes Care has announced its Tandem t:slim X2 insulin pump is now compatible with Abbott’s FreeStyle Libre 3 Plus ...

Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, received approval for use with the ultra-rapid-acting insulin ...

The strategy and product exec said Tandem aims to give patients options and reach more people who haven’t yet used insulin ...

SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

The product is made by Tandem Diabetes Care, which sells touchscreen insulin pumps and an accompanying app to help dose the medicine. Around 300,000 people use the technology.

The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including ...

Tandem Diabetes Care's t:slim X2 insulin pump becomes the first to integrate with Abbott's FreeStyle Libre 2 Plus Sensor for US users.

Medical device firm Tandem Diabetes Care has produced data showing predictive software in an insulin pump can reduce time spent in hypoclycaemia compared with sensor-augmented pumps in type 1 disease.

RBC sets a $65 price target for Tandem, citing strong growth prospects and margin improvements. RBC expects 51% gross margins in 2024, with the Mobi pump launch driving long-term profitability. 9 ...

Tandem Diabetes Care, Inc. and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t: slim X2™ insulin pump users can now access full ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is no ...